


HEMOCLOT QUANTI-V-L

HEMOCLOT Quanti. V-L is now CE Marked and 510(k) Approved
 THE RIGHT SOLUTION FOR SOLVING THE LABOTARORY
 ISSUES FACED WHEN TESTING FACTOR V-LEIDEN





Factor V mutated at position 506 (R506Q), also called Factor V-Leiden (V-L), induces a resistance to the action of Activated Protein C, and is associated with an increased thrombotic risk.

REGULATION OF BLOOD COAGULATION THROUGH THE PROTEIN C/PROTEIN S AND AT III PATHWAYS


A novel, specific and quantitative assay for measuring Factor V-leiden, with a single step clotting method (HEMOCLOT Quanti-V-L-ACK065K)

PRINCIPLE

- Clotting method for measuring quantitatively Factor V-L (Factor V-Leiden) concentration in citrated plasma, by its resistance to the action of Activated Protein C (APC).
- The diluted plasma is mixed with purified clotting Factors, in presence of APC, in a constant and optimised concentration (R1: Prothrombin, Fibrinogen, Protein S and APC). The purified Factor Xa in presence of Phospholipids and calcium (R2) is then added. Clotting is initiated by addition of calcium (Ca²⁺) and the clotting times are then recorded. In presence of APC clotting time is inversely proportional to the concentration of factor V-L. There is an inverse linear relationship, on a linear (CT)-logarithmic (FVL) graph paper, between the factor V-L concentration and the corresponding clotting time.



- ➔ **One step clotting method** developed and designed using highly purified human coagulation proteins.
- ➔ **Fully quantitative assay** for the measurement of Factor V-Leiden (V-L) on citrated plasma.
- ➔ Performed using **only one clotting test**.
- ➔ **Excellent discrimination** (clotting time and Factor V-L concentrations) between normal, heterozygous and homozygous patients (for the R506Q mutation).
- ➔ Highly robust assay offering **excellent intra- (<3%) and inter-assay (<5%)** reproducibilities.
- ➔ **No interference** of heparin or dicoumarol therapy.
- ➔ **Easy to perform, cost effective and reliable assay, fully automatable on laboratory instruments.**



FACTOR V-LEIDEN CONCENTRATIONS

- Normals (N = 30) : < 5 %
- Heterozygous (N = 8) : 35 to 60 %
- Homozygous (N = 2) : > 100 %
- Dicoumarol therapy (non mutated) (N = 10) < 5 %